Cabaletta Bio (CABA)

• Market cap: $127M
• 1 day: -5.11%
• 5 days: 18.18%
• 1 month: 10.17%
• 3 months: -42.48%
• 6 months: -63.84%
• Year to date: 11.59%
• 1 year: -87.30%
• 5 years: -83.92%
• 10 years: -74.00%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Employees: 154

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

64% more call options, than puts

Call options by funds: $992K | Put options by funds: $604K

31% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 35

8.89% less ownership

Funds ownership: 107.82% [Q2] → 98.93% (-8.89%) [Q3]

15% less funds holding

Funds holding: 142 [Q2] → 120 (-22) [Q3]

41% less capital invested

Capital invested by funds: $389M [Q2] → $228M (-$161M) [Q3]

51% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 41

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 131% upside
• Avg. target: $12.33 374% upside
• High target: $25 862% upside

3 analyst ratings

• positive: 1 33%
• neutral: 2 67%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 31% 1-year accuracy 54 / 173 met price target	862% upside $25	Buy Reiterated	17 Jan 2025
Evercore ISI Group Gavin Clark-Gartner 30% 1-year accuracy 3 / 10 met price target	131% upside $6	In-Line Downgraded	20 Dec 2024
Wells Fargo Derek Archila 42% 1-year accuracy 15 / 36 met price target	131% upside $6	Equal-Weight Downgraded	19 Dec 2024